Business Wire

GSMA

8.10.2019 08:02:12 CEST | Business Wire | Press release

Share
GSMA: Russian Mobile Operators to Lead Commonwealth of Independent States in 5G Deployments

Russia will lead the Commonwealth of Independent States (CIS)1 in the commercialisation of 5G services, with the region’s other markets all launching 5G networks by 2025, according to the GSMA’s Mobile Economy: Russia & CIS 2019 report, which was published today at the Mobile 360 Series – Eurasia event in Moscow. The CIS region will have around 54 million 5G connections by 2025, an adoption rate of 13 per cent. Operators are forecast to invest $39 billion in mobile infrastructure between 2019 and 2025, of which over 70 per cent will be 5G-specific.

“5G networks have the potential to transform the digital economy for businesses and citizens alike and our latest report highlights how Russia and the CIS region is preparing to enter this exciting new era,” said Mats Granryd, Director General of the GSMA. “However, in order to capitalise on the tremendous potential of 5G in driving socio-economic growth, regional governments and regulators must adopt policies, such as access to spectrum, that encourage inward investment and encourage the development of the mobile industry.”

4G Networks Growing, Subscriber Adds Slowing

The CIS region had 235 million unique mobile subscribers at the end of 2018, with Russia, Ukraine and Uzbekistan together accounting for 80 per cent. The region has a high unique subscriber penetration rate of 81 per cent, notably in Russia which is approaching saturation point. Future growth will be limited to less than 9 million new unique subscribers in the CIS by 2025. However, the region is also seeing an accelerated shift to mobile broadband driven by greater demand for data-intensive services and higher speeds. 4G is set to become the region’s leading mobile technology in 2021, and will account for over two-thirds of total connections in 2025.

Policies to Support the Digital Economy

The report highlights how delivering 5G connectivity will increase capital intensity for operators, while current uncertainty around spectrum access could be a potential barrier to releasing value into the digital economy. 5G networks have the potential to underpin a range of innovative solutions for businesses and consumers; however, policymakers should also harness the power of 5G to drive growth and the transformation of traditional industries. The regulatory framework should foster the mobile industry’s development within an environment that is conducive to investment. This should be underpinned by a comprehensive national 5G development plan.

Mobile Contributing to the Economy and Employment

The mobile industry contributed $101 billion or 4.7 per cent of GDP to the CIS regional economy in 2018, which is forecast to increase to $122 billion (5.1 per cent of GDP) by 2023. In 2018, the industry contributed 620,000 jobs through direct employment or indirectly through activity in the wider economy. An additional $12 billion was raised in 2018 via general taxation. 5G-related technologies are expected to contribute $34 billion to regional economy over the next 15 years.

Regional Innovation Underpinned by Mobile Connectivity

The report also highlights the potential for operators to expand their businesses beyond traditional communications in areas such as the Internet of Things (IoT), where smart homes and smart buildings will be two key growth verticals out to 2025. The mobile industry is also exploring and implementing applications of artificial intelligence (AI) and blockchain technologies, as well as injecting greater funds into the start-up ecosystem to protect itself from disruption and diversify the revenue mix.

The new report The Mobile Economy Russia & CIS 2019 is authored by GSMA Intelligence . To access the full report and related infographics, please visit: https://www.gsma.com/r/mobileeconomy/russia-cis/

-ENDS-

Notes to Editors

  1. The Commonwealth of Independent States (CIS) are Armenia, Azerbaijan, Belarus, Georgia, Moldova, Kazakhstan Kyrgyzstan, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye